Nautilus Biotechnology Partners with Weill Cornell Medicine-Qatar and The Michael J. Fox Foundation for Parkinson's Disease Research

Nautilus Biotechnology (NAUT) has partnered with Weill Cornell Medicine-Qatar and The Michael J. Fox Foundation to study the alpha-synuclein protein's role in Parkinson's disease. The project is backed by a $1.6 million grant and utilizes Nautilus's advanced single-molecule proteomics platform. Despite being in the development stage, Nautilus has strong financial health with a current ratio of 14.95 and a debt-to-equity ratio of 0.16. However, investors should be aware of the company's developmental stage and inherent sector risks.